Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib

Abstract

Erlotinib or other novel protein kinase pathway inhibitors should be evaluated further in patients with aggressive thyroid cancer variants, who may exhibit these and perhaps other tyrosine kinase mutations.